Mortensen S A, Boesgaard S, Arendrup H C, Andersen L W, Aldershvile J
Ugeskr Laeger. 2000 Oct 30;162(44):5895-900.
In carefully selected patients with end-stage heart failure heart transplantation has developed from an experimental procedure to standard therapy during the last 30 years. It is currently accepted as a procedure for prolonging life and also for improving quality of life. According to the Registry of the International Society for Heart and Lung Transplantation the overall one-year actuarial survival is 79% and 10-year survival barely 50%. Nine years after the start of the Heart Transplant Program at Rigshospitalet the overall actuarial survival of 157 consecutive patients is 66%. Due to the limited donor access a decline of heart transplant recipients has been recorded during the late nineties. Mechanical replacement of the heart may develop from technological advances and possibly this therapy may gain a complementary status in heart failure, however the human biological replacement is currently the standard.
在过去30年里，对于精心挑选的终末期心力衰竭患者，心脏移植已从一种实验性手术发展成为标准治疗方法。目前，它被公认为一种既能延长生命又能改善生活质量的手术。根据国际心肺移植协会登记处的数据，总体一年精算生存率为79%，十年生存率仅为50%。在里格霍斯皮塔尔心脏移植项目启动九年后，157例连续患者的总体精算生存率为66%。由于供体来源有限，在九十年代后期，心脏移植受者数量有所下降。心脏的机械替代可能会随着技术进步而发展，这种治疗方法可能会在心力衰竭治疗中获得辅助地位，然而目前人类生物替代仍是标准治疗方法。
